90 studies found for:    "Neisseria meningitidis"
Show Display Options
Rank Status Study
1 Completed Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
Condition: Neisseria Meningitidis
Intervention: Biological: MenBvac
2 Completed
Has Results
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
Conditions: Meningitis;   Meningococcemia;   Neisseria Meningitidis
Intervention: Biological: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
3 Completed
Has Results
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Hib-MenCY-TT vaccine;   Biological: Hib-MenC-TT vaccine;   Biological: Menjugate ®;   Biological: Infanrix penta ®;   Biological: Infanrix hexa ®
4 Completed
Has Results
Dose Comparison Study of Menactra® in US Children
Conditions: Meningitis;   Meningococcal Infection;   Neisseria Meningitidis
Intervention: Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
5 Completed
Has Results
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: MenHibrix (Hib-MenCY-TT);   Biological: Infanrix® Penta;   Biological: Prevenar®;   Biological: ActHIB®;   Biological: Meningitec®;   Biological: M-M-R®II;   Biological: Varivax®;   Biological: PedvaxHIB®
6 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
Conditions: Meningococcal Infection;   Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine;   Haemophilus Influenza b Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014);   Biological: PedvaxHIB;   Biological: Prevnar;   Biological: M-M-R II;   Biological: Varivax
7 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
Conditions: Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine;   Haemophilus Influenza Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014;   Biological: ActHIB;   Biological: Pediarix/Infanrix Penta
8 Completed Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
Condition: Invasive Neisseria Meningitidis Serogroup Diseases
Intervention: Biological: Meningococcal vaccine GSK134612
9 Completed N. Meningitidis Carriage Study
Condition: Infections, Meningococcal
Interventions: Procedure: Posterior pharyngeal swab;   Other: Data collection
10 Completed
Has Results
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
Condition: Invasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y
Interventions: Biological: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix);   Biological: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix);   Biological: Infanrix®;   Biological: ActHIB®;   Biological: Pediarix®
11 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
12 Completed Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Intervention: Biological: Haemophilus influenzae type b- and meningococcal (vaccine)
13 Completed
Has Results
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
Conditions: Tetanus;   Hepatitis B;   Haemophilus Influenzae Type b;   Poliomyelitis;   Acellular Pertussis;   Diphtheria;   Neisseria Meningitidis
Interventions: Biological: GSK2202083A vaccine;   Biological: Prevenar 13®;   Biological: Infanrix hexa™;   Biological: Menjugate®;   Biological: Rotarix™
14 Completed
Has Results
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: MenitorixTM;   Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: PrevenarTM;   Biological: MeningitecTM;   Biological: NeisVac-CTM;   Biological: InfanrixTM hexa;   Biological: InfanrixTM penta;   Biological: InfanrixTM IPV/Hib;   Biological: InfanrixTM IPV
15 Active, not recruiting Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: Hib-MenCY-TT vaccine (GSK792014);   Biological: Pediarix®;   Biological: Rotarix®;   Biological: Prevnar 13®;   Biological: PedvaxHIB®;   Biological: Havrix®
16 Active, not recruiting Spanish Mixed HEXA/PENTA/HEXA Schedule
Conditions: Neisseria Meningitidis;   Bacterial Infections;   Virus Diseases
Interventions: Biological: PR5I (V419);   Biological: Pediacel;   Biological: NeisVac-C;   Biological: RotaTeq;   Biological: Prevenar 13
17 Completed
Has Results
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: GSK2197870A;   Biological: Prevenar™;   Biological: Menitorix™;   Biological: Pediacel™;   Biological: Menjugate™
18 Completed Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
Condition: Neisseria Meningitidis
Intervention: Biological: Meningococcal outer membrane vesicle vaccine "MenBVac"
19 Active, not recruiting Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
Conditions: Neisseria Meningitidis;   Bacterial Infections;   Virus Diseases
Interventions: Biological: Hexavalent vaccine;   Biological: NeisVac-C;   Biological: Prevenar 13;   Biological: RotaTeq;   Biological: Nimenrix;   Biological: M-M-RVAXPRO
20 Completed Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines
Conditions: Neisseria Meningitidis;   Bacterial Infections;   Virus Diseases
Interventions: Biological: V419 (PR5I);   Biological: Prevenar 13;   Biological: NeisVac-C;   Biological: MENJUGATE;   Biological: MENITORIX;   Biological: M-M-RVAXPRO

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years